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I. General Procedures 
 
General. Unless otherwise noted, all chemicals and reagents were obtained from 
commercial suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further 
purification. Silica gel chromatography was carried out using AMD Silica Gel 60, 230-400 
mesh. 1H and 13C NMR spectra were taken using a Bruker Prodigy 400 MHz instrument 
and are internally referenced to the residual solvent peak (chloroform). Data for 1H NMR 
are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublets, dt = doublet of 
triplets, ddd = doublet of doublet of doublets), coupling constant (Hz), integration. 
Sonication was performed using a Qsonica Q500 sonicator. High-resolution mass spectra 
were obtained at the Catalysis Center of California Institute of Technology. Synthetic 
reactions were monitored using thin layer chromatography (Merck 60 gel plates) using a 
UV-lamp for visualization. 
 
Chromatography. Analytical reversed-phase high-performance liquid 
chromatography (HPLC) was carried out using an Agilent 1200 series instrument and a 
poroshell C18 column (4.6 × 50 mm, 5 µm) with water and acetonitrile as the mobile phase 
and visualization at 254 nm for library screening. Analytical normal-phase HPLC was 
carried out using an Agilent 1200 series instrument and chiral columns Chiralpak IC (4.6 
mm × 25 cm) with n-hexane and isopropanol as the mobile phase and visualization at 254 
nm for chiral separation. Gas chromatography (GC) analyses were carried out using an 
Agilent 7820A gas chromatograph, FID detector, and a J&W HP-5 column (30 m × 0.32 
mm, 0.25 μm film) and CycloSil-B column (30 m × 0.25 mm, 0.25 μm film). Gas 
chromatography-mass spectrometry (GC-MS) analyses were carried out using a Shimadzu 
GCMS-QP2010SE system and J&W HP-5m column. 
 
Cloning and site-saturation mutagenesis. pET22b(+) containing a C-terminal 6x-
His tag was used as a cloning and expression vector for all enzymes described in this study. 
Site-saturation mutagenesis was performed using a modified QuikChangeTM mutagenesis 
protocol (1). Primer sequences are available upon request. The PCR products were digested 
with DpnI, gel purified, and fragments were assembled using Gibson Mix (2). The ligation 
mixture was used to directly transform E. coli strain BL21 E. cloni® (Lucigen). Cells were 
grown using Luria-Bertani medium (LB) or Hyperbroth (AthenaES) (HB) with 0.1 mg/mL 
ampicillin (LBamp or HBamp). Electrocompetent E. coli cells were prepared following the 
protocol of Sambrook et al. (3). T5 exonuclease, Phusion polymerase, and Taq ligase were 
purchased from New England Biolabs (NEB, Ipswich, MA). M9-N minimal medium 
(abbreviated as M9-N buffer; pH 7.4) was used as a buffering system for whole cells, 
lysates, and purified proteins, unless otherwise specified. M9-N buffer was used without a 
carbon source; it contains 47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM 
MgSO4, and 0.1 mM CaCl2. 
 
Determination of hemeprotein concentration. 
1. Preparation of cell lysate: Aliquots of ~3 mL OD600 = 60 cells were prepared in 
15 mL conical tubes, which were then placed on wet ice. Cells were lysed by sonication 





amplitude. The sonicated samples were then transferred to two Eppendorf tubes, and then 
centrifuged down (14,000 rpm, 15 min, 4 ºC). The supernatants (~2.5 mL) were then 
collected to a 5-mL glass vial for analysis. 
2. Hemechrome assay for protein concentration measurement: A solution of 
NaOH/pyridine was prepared by mixing 1 mL of NaOH aqueous solution (1 M), 2 mL of 
water and 2 mL of pyridine. To 4.5 mL of NaOH/pyridine solution, 22.5 μL of K3Fe(CN)6 
aqueous solution (0.1 M) was added to make solution 1. A background solution was 
prepared by mixing 500 μL M9-N and 500 μL of the NaOH/pyridine solution, which was 
used for UV background subtraction. When measuring samples with a UV spectrometer, a 
spectrum of a mixed solution (oxidized spectrum) with 500 μL cell lysate + 500 μL 
solution 1 was taken at the wavelength range 380 nm to 650 nm. Subsequently, 5 μL of 
dithionite solution (0.5 M in 0.1 M NaOH solution) was added to the same sample and 
mixed by pipetting; a spectrum of this solution (reduced spectrum) was taken at 380 nm to 
650 nm. The protein concentration was calculated using the extinction coefficient and 
dilution factor (2X dilution in volume): ε_[557reduced ‒ 540oxidized] = 23.98 mM‒1cm‒1 (4).  
 
Expression of P450 and P411 proteins. E. coli BL21 E. cloni® cells carrying a 
plasmid encoding a P411 variant were grown overnight in 5 mL LBamp (37 ºC, 220 rpm). 
The pre-culture was used to inoculate 45 mL of HBamp in a 125 mL Erlenmeyer flask; this 
culture was incubated at 37 ºC, 220 rpm for 2 h and 15 min. Cultures were then cooled on 
ice for 40 min, and expression was induced with isopropyl β-d-1-thiogalactopyranoside 
(abbreviated as IPTG; final concentration: 0.5 mM) and 5-aminolevulinic acid (abbreviated 
as ALA; final concentration: 1.0 mM). Expression was conducted at room temperature (24 
ºC), at 140 rpm, for 20 h (± 20 min). Cultures were then centrifuged (4,500 × g, 5 min, 4 
ºC), and the pellets were resuspended to an OD600 of 60 in M9-N buffer. Aliquots of the 
cell suspension (3 mL) were used to determine protein concentration after lysis by 
sonication. The expression level in OD600 = 60 lysates is typically in the range of 6‒13 μM 
for the P411-C10 variant. 
 
Biotransformations. All the biocatalytic reactions were set up in an anaerobic 
chamber (oxygen level: < 40 ppm). Resuspended cells (340 µL, diluted to a given OD600 
with M9-N buffer) were added to 2 mL vials, followed by D-glucose (40 µL, 250 mM in 
M9-N), alkyne (10 µL of an EtOH stock, 400 mM), and ethyl diazoacetate (EDA, 10 µL 
of an EtOH stock, 400 mM). Final concentrations were typically 10.0 mM alkyne, 10.0 
mM EDA, and 25 mM D-glucose; final reaction volume was 400 µL. The vials were sealed, 
shaken inside the anaerobic chamber at room temperature for a set time (600 rpm). After 
the reaction was completed and the vials removed from the anaerobic chamber, internal 
standard 1,3,5-trimethoxybenzene, 1,2,3-trimethoxybenzene or ethyl 2-phenylacetate (20 
μL of 20 mM stock solution in toluene) was added followed by mixed solvent (hexane/ethyl 
acetate = 1:1, 1.0 mL). The mixture was transferred to a 1.7 mL Eppendorf tube, and then 
subjected to vortexing (15 s × 3) and centrifugation (14,000 rpm, 5 min) to completely 
separate the organic and aqueous layers. A sample of the organic layer (0.8 mL) was 
transferred to a vial for GC analysis. The procedure for preparative-scale enzymatic 
reactions is outlined in detail (See Section VI). 
 





libraries generated employing the “22c-trick” method (1) or collections of heme protein 
variants) were screened in 96-well plates. 
E. coli libraries for P411 variants were cultured in LBamp (300 µL/well) at 37 ºC, 250 
rpm and 80% relative humidity overnight. HBamp (950 µL/well) was inoculated with the 
pre-culture (50 µL/well) and incubated at 37 ºC, 230 rpm, 80% humidity for 2 h and 45 
min. The plates were cooled on ice for 30 minutes, and expression was induced with 0.5 
mM IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). Expression was 
conducted at 22 ºC and 220 rpm for 20 h.  
The cells were pelleted (4,500 × g, 5 min, 4 ºC) and resuspended with M9-N buffer 
(340 µL/well) and D-glucose solution (40 µL/well, in M9-N). The 96-well plate was then 
transferred to an anaerobic chamber. In the anaerobic chamber, alkyne (10 µL/well, 400 
mM in EtOH) and EDA (10 µL/well, 400 mM in EtOH). The plate was sealed with an 
aluminum foil and shaken inside the anaerobic chamber at 600 rpm. 
After 6 h, the seal was removed and acetonitrile (580 µL/well) and internal standard 
p-methylanisole (20 mM in acetonitrile, 20 µL/well) were added. The plate was tightly 
sealed with a reusable silicone mat, vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min). 
The supernatant (200 µL/well) was filtered through an AcroPrep 96-well filter plate (0.2 
µm) into a shallow-well plate for reversed-phase HPLC analysis (C18 Poroshell column, 






II. Directed Evolution of P411-C10 for Internal Cyclopropenation 
E. coli harboring
P411-C10 variants
M9-N buffer (pH 7.4)
room temp., 6 h
Ph






   
Figure S1. Directed evolution of P411-C10 for internal cyclopropene synthesis. 
Reaction conditions: 10 mM 1-phenylbutyne, 10 mM EDA, E. coli harboring P411-C10 
variants (OD600=60 for C10, OD600=30 for C10-W, OD600=15 for the rest), D-glucose (25 
mM), M9-N buffer/EtOH (19:1), anaerobic, 6 h. Product formation was quantified by gas 
chromatography (GC) and TTNs were determined based on protein concentration. The 

















Table S1. Detailed information of the evolutionary lineage. 
P411-C10 variant TTN ee 
C10 55 ± 2 >99% 
C10-Y263W (W) 620 ± 15 >99.9% 
C10-A87V 110 ± 10 >99.9% 
C10-Y263W Q437I (WI) 1280 ± 40 >99.9% 
C10-Y263W Q437I S72F 
(WIF) 
2450 ± 60 >99.9% 
C10-Y263W Q437I L436R 
S72F (WIRF) 
2680 ± 100 >99.9% 
Evolutionary details: 
Round # Parent 
Sites targeted for site-
saturation mutagenesis 
Beneficial mutations obtained 
1 C10 87, 263, 327, 438 
A87V (~2-fold improvement) 
T327C (~1.5-fold improvement) 








78, 181, 328, 437 
Q437I (~2-fold improvement) 
Q437V (~1.8-fold improvement) 
4 C10-WI 72, 87, 266, 438 S72F (~2-fold improvement) 























Figure S2. Directed evolution of WIRF for internal cyclopropene synthesis. Reaction 
conditions: 10 mM 1-(4-chlorophenyl)butyne, 10 mM EDA, E. coli harboring P411-C10 
variants (OD600=30 for C10 and WIRF, OD600=20 for the rest), D-glucose (25 mM), M9-
N buffer/EtOH (19:1), anaerobic, 6 h. Product formation was quantified by gas 
chromatography (GC) and TTNs were determined based on protein concentration. The 
active-site structure of P411-E10 variant (pdb: 5UCW) was used to guide site-saturation 
mutagenesis. 
Table S2. Detailed information of the evolutionary lineage. 
P411-C10 variant TTN ee 
C10 110 ± 10 >99% 
WIRF 300 ± 10 >99% 
WIRF-S332G 1440 ± 40 >99.9% 
WIRF-S332G G72A 
(WIRF_GA) 
1610 ± 50 >99.9% 
WIRF-S332G G72A E70K 
(WIRF_GAK) 
2140 ± 40 >99.9% 
Evolutionary details: 
Round # Parent 
Sites targeted for site-
saturation mutagenesis 
Beneficial mutations obtained 




74, 85, 268, 328 G74A (~1.1-fold improvement) 
3 WIRF_GA 70, 269, 327, 436 E70K (~1.3-fold improvement) 
 
Note: All the C10 variants (including the initial parent C10) here have the FAD domain 
truncated. Construction of the full-length P411 variants based on WIRF and WIRF_GAK 
by adding the FAD domain back revealed lower catalytic efficiency for internal 







Figure S3. Kinetics of whole-cell cyclopropenation with different substrates and 
enzyme variants. Reaction conditions: 10 mM 1-phenylbutyne or 1-(4-
chlorophenyl)butyne, 10 mM EDA, E. coli harboring P411 variants, C10, WIRF or 
WIRF_GAK (OD600=15 for all), D-glucose (25 mM), M9-N buffer/EtOH (19:1), 
anaerobic. Reactions (in duplicate) were quenched at certain time points (20 min, 40 min, 
60 min, 80 min, 100 min and 120 min), and product formation was quantified by gas 
chromatography (GC) using 1,3,5-trimethoxybenzene as the internal standard. Relative 
activity was normalized by protein concentration. (Note: PhC4 as the abbreviation for 1-
phenylbutyne and pClPhC4 as the abbreviation for 1-(4-chlorophenyl)butyne.) 
 
The whole-cell kinetic studies with two different substrates indicate that the evolved 
enzyme variants exhibit higher reaction rates (1-phenylbutyne: 17-fold improvement in 
initial rate from C10 to WIRF; 1-(4-chlorophenyl)butyne: 4.5-fold improvement in initial 
rate from WIRF to WIRF_GAK) and probably longer lifetime (1-(4-chlorophenyl) 
butyne: product formation with WIRF slowed down after ~100 min while variant 






















































































Figure S4. Alkyne substrates. 
General procedure for internal aromatic alkyne synthesis (1b and 1d to 1l): 
 
To a 100-mL flask were added aryl bromide or iodide (10.0 mmol, 1.0 equiv.), 2-pentynoic 
acid (1.18 g, 12.0 mmol, 1.2 equiv.), PdCl2(Ph3P)2 (70 mg, 0.1 mol, 1 mol%), 1,4-
bis(diphenylphosphino)butane (dppb, 86 mg, 0.2 mmol, 2 mol%) and anhydrous DMSO 
(30 mL). The mixture was stirred at room temperature for 3 minutes, and then the flask 
was capped, degassed and charged with N2. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 
4.4 mL, 30 mmol, 3.0 equiv.) was added to the reaction under N2. The reaction was stirred 
at 110 °C for 12 hours before being cooled to room temperature, quenched by NH4Cl (sat. 
aq., 20 mL) and diluted with water (30 mL). The product was extracted by ether (25 mL × 
3). The combined organic layer was then washed with water (30 mL) and brine (30 mL), 
and dried over magnesium sulfate. The organic layer was filtered and concentrated under 
reduced pressure. Distillation of the crude mixture under high vacuum (<100 Pa, 80-125 




Compound 1b was prepared following the general procedure using 
the corresponding aryl bromide. The reaction was set up in 80-
mmol scale and distillation afforded the alkyne 1b as a colorless 
liquid (11.4 g, 86%). 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 
8.7 Hz, 2H), 2.41 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) 








Compound 1d was prepared following the general procedure using the 
corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) δ 7.39 (td, J 
= 7.6, 1.8 Hz, 1H), 7.24 (dddd, J = 8.2, 7.2, 5.2, 1.8 Hz, 1H), 7.10 – 
7.00 (m, 2H), 2.47 (q, J = 7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 164.14, 161.66 (d, J = 250.9 Hz), 133.70, 133.69 (d, J = 1.6 Hz), 129.28, 129.20 
(d, J = 8.0 Hz), 123.93, 123.90 (d, J = 3.7 Hz), 115.57, 115.36 (d, J = 21.3 Hz), 112.65, 




Compound 1e was prepared following the general procedure using 
the corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.36 
(dd, J = 8.8, 5.4 Hz, 2H), 6.97 (t, J = 8.8 Hz, 2H), 2.40 (q, J = 7.5 
Hz, 2H), 1.23 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 163.39, 160.93 (d, J = 
249.2 Hz), 133.46, 133.38 (d, J = 8.2 Hz), 120.20, 120.17 (d, J = 3.6 Hz), 115.62, 115.40 




Compound 1f was prepared following the general procedure 
using corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 
7.21 (dd, J = 8.3, 7.6 Hz, 1H), 7.02 (dt, J = 7.6, 1.2 Hz, 1H), 6.96 
(dd, J = 2.6, 1.4 Hz, 1H), 6.85 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 3.82 (s, 3H), 2.44 (q, J = 7.5 
Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 159.38, 129.36, 125.13, 




Compound 1g was prepared following the general procedure 
using corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 
7.53 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 2.44 (q, J = 7.5 
Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 131.89, 129.38 (q, J = 
32.7 Hz), 128.04 (q, J = 3.8 Hz), 125.24 (q, J = 38.7 Hz), 124.17 (q, J = 273.0 Hz), 94.62, 




Compound 1h was prepared following the general procedure 
using corresponding aryl bromide. 1H NMR (400 MHz, 
CDCl3) δ 7.41 (d, J = 8.7 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 
6.52 (t, J = 73.7 Hz, 1H), 2.43 (q, J = 7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 150.48, 133.17, 121.47, 119.41, 118.48, 115.90, 113.31 (t, J = 260.8 Hz), 








Compound 1i was prepared following the general procedure using 
corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.29 (d, 
J = 8.2 Hz, 2H), 7.09 (d, J = 7.7 Hz, 2H), 2.41 (q, J = 7.5 Hz, 2H), 
2.33 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 137.57, 131.52, 




Compound 1j was prepared following the general procedure 
using corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 
7.33 (d, J = 8.9 Hz, 2H), 6.81 (d, J = 8.9 Hz, 2H), 3.80 (s, 3H), 
2.40 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 159.11, 




Compound 1k was prepared following the general procedure 
using corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) δ 
7.26 (d, J = 1.9 Hz, 1H), 7.24 (d, J = 8.2 Hz, 1H), 7.14 (dd, J = 
8.2, 1.9 Hz, 1H), 2.40 (q, J = 7.5 Hz, 2H), 2.33 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H). 13C NMR 





Compound 1l was prepared following the general procedure 
using corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) 
δ 7.24 (dd, J = 8.3, 2.0 Hz, 1H), 7.21 (d, J = 2.0 Hz, 1H), 6.75 
(d, J = 8.3 Hz, 1H), 3.84 (s, 3H), 2.42 (q, J = 7.5 Hz, 2H), 2.20 (s, 3H), 1.25 (t, J = 7.5 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 157.43, 133.90, 130.37, 126.69, 115.69, 109.78, 89.78, 




Hex-3-yn-1-ol (2.94 g, 30 mmol, 1.0 equiv.) was dissolved in 
anhydrous DMF (60 mL) in a 250-mL flask. NaH (1.44 g, 60% in 
mineral oil, 36 mmol, 1.2 equiv.) was slowly added to the solution in portions over 20 min 
at 0 °C. The resulting mixture was stirred at 0 °C for 1.5 h before slow addition of ethyl 
iodide (3.6 mL, 45 mmol, 1.5 equiv.). The reaction was slowly warmed to room 
temperature over 30 min and then stirred for additional 2 h before being quenched by 
NH4Cl (sat. aq., 20 mL) and diluted with water (30 mL). The product was extracted by 
ether (40 mL × 3). The combined organic layer was then washed with water (50 mL × 2) 
and brine (50 mL), and dried over sodium sulfate. The organic layer was filtered and 





column using hexane: ethyl acetate (100:0 to 20:1) as eluents to afford the alkyne 1m as a 
clear liquid (3.72 g, 98% yield). 1H NMR (400 MHz, CDCl3) δ 3.51 (td, J = 7.1, 5.3 Hz, 
4H), 2.42 (tt, J = 7.2, 2.4 Hz, 2H), 2.16 (qt, J = 7.5, 2.4 Hz, 2H), 1.20 (t, J = 7.0 Hz, 3H), 
1.11 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 82.88, 76.15, 69.42, 66.36, 20.28, 




Oct-2-yn-1-ol (3.79 g, 30 mmol, 1.0 equiv.) was dissolved in 
anhydrous DMF (60 mL) in a 250-mL flask. NaH (1.44 g, 
60% in mineral oil, 36 mmol, 1.2 equiv.) was slowly added to the solution in portions over 
20 min at 0 °C. The resulting mixture was stirred at 0 °C for 1.5 h before slow addition of 
iodomethane (2.8 mL, 45 mmol, 1.5 equiv.). The reaction was slowly warmed to room 
temperature over 30 min and then stirred for additional 2 h before being quenched by 
NH4Cl (sat. aq., 20 mL) and diluted with water (30 mL). The product was extracted by 
ether (40 mL × 3). The combined organic layer was then washed with water (50 mL × 2) 
and brine (50 mL), and dried over sodium sulfate. The organic layer was filtered and 
concentrated under reduced pressure. The crude product was purified through a silica 
column using hexane: ethyl acetate (100:0 to 20:1) as eluents to afford the alkyne 1n as a 
clear liquid (4.04 g, 96% yield). 1H NMR (400 MHz, CDCl3) δ 4.07 (t, J = 2.2 Hz, 2H), 
3.36 (s, 3H), 2.21 (tt, J = 7.2, 2.2 Hz, 2H), 1.56 – 1.48 (m, 2H), 1.41 – 1.26 (m, 4H), 0.89 
(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 87.39, 75.80, 60.38, 57.53, 31.19, 28.47, 






IV. Synthesis and Characterization of Standard Products 
General procedure for internal cyclopropene synthesis: 
 
To a 20 mL vial was added alkyne (1.5 mmol, 1.0 equiv.), Rh2(OAc)4 (6.6 mg, 2 mol%) 
and DCM (3 mL). A solution of EDA (3.0 mmol, 2.0 equiv.) in DCM (3 mL) was added 
dropwise to the reaction mixture over 10 hours through a syringe pump. The reaction was 
stirred at room temperature for another 6 hours. Evaporation of the organic solvent and 
purification by silica column chromatography using hexane and ethyl acetate as eluents 
afforded cyclopropene products (or products in mixture form with carbene dimers, diethyl 
maleate and diethyl fumarate). For most cyclopropene products, further purification by 
C18 column reverse-phase chromatography using acetonitrile and water as eluents was 
required to separate the cyclopropene products from the carbene dimers. The cyclopropene 
products were obtained mostly in 1% to 10% yields. 
 
Notes: 
1. For the reactions giving low yields, the remaining substrates (>80%) were recovered and 
the reactions were set up again following the same procedure in order to get enough 
cyclopropene product for analysis. 
2. Aromatic cyclopropenes prepared here are not stable for very long in neat form 
(estimated t1/2 ~ days to a week at room temperature, t1/2 ~ weeks at ‒20°C); but the 
cyclopropenes can last significantly longer in solution form, especially when using less 
sensitive organic solvents, such as hexane, ethyl acetate, ether and more. One major 
decomposition pathway of cyclopropenes is dimerization or polymerization, as discussed 
in ref (5). 
 
Ethyl 2-ethyl-3-phenylcycloprop-2-ene-1-carboxylate (2a) 
 
1H NMR (400 MHz, CDCl3) δ 7.44 – 7.37 (m, 2H), 7.35 – 7.29 (m, 2H), 
7.27 – 7.22 (m, 1H), 4.15 – 4.02 (m, 2H), 2.62 (q, J = 7.5 Hz, 2H), 2.38 
(s, 1H), 1.26 (t, J = 7.5 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 176.05, 129.48, 128.75, 128.70, 127.19, 111.64, 104.65, 
60.25, 22.34, 19.30, 14.57, 12.21. HRMS (TOF) m/z: 217.1194 (M+H+); calc. for 
[C14H16O2+H+]: 217.1223. 
 
Ethyl 2-ethyl-3-(4-chorophenyl)cycloprop-2-ene-1-carboxylate (2b) 
 
1H NMR (400 MHz, CDCl3) δ 7.45 – 7.31 (m, 4H), 4.22 – 4.07 (m, 
2H), 2.69 (q, J = 7.5 Hz, 2H), 2.44 (s, 1H), 1.32 (t, J = 7.5 Hz, 3H), 
1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.71, 
134.62, 130.63, 129.08, 125.79, 112.55, 103.78, 60.36, 22.34, 19.30, 








Ethyl 2-methyl-3-phenylcycloprop-2-ene-1-carboxylate (2c) 
 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.44 (m, 2H), 7.42 – 7.36 (m, 2H), 
7.35 – 7.28 (m, 1H), 4.16 (qd, J = 7.1, 3.7 Hz, 2H), 2.43 (s, 1H), 2.33 (s, 
3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.92, 
129.42, 128.76, 128.71, 127.29, 106.51, 105.40, 60.30, 22.72, 14.59, 
10.89. HRMS (TOF) m/z: 203.1054 (M+H+); calc. for [C13H14O2+H+]: 203.1067. 
 
Ethyl 2-ethyl-3-(2-fluorophenyl)cycloprop-2-ene-1-carboxylate (2d) 
 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.27 (m, 2H), 7.16 (td, J = 7.5, 1.1 
Hz, 1H), 7.10 (ddd, J = 9.3, 8.2, 1.0 Hz, 1H), 4.23 – 4.09 (m, 2H), 2.74 
(qdd, J = 7.5, 2.4, 0.8 Hz, 2H), 2.43 (s, 1H), 1.30 – 1.22 (m, 6H). 13C 
NMR (101 MHz, CDCl3) δ 175.84, 161.02 (d, J = 253.5 Hz), 130.71 (d, 
J = 2.8 Hz), 130.49 (d, J = 8.0 Hz), 124.35 (d, J = 3.7 Hz), 115.80 (d, J = 15.4 Hz), 115.57 
(d, J = 20.5 Hz), 114.08 (d, J = 3.8 Hz), 98.73 (d, J = 1.8 Hz), 60.34, 21.23, 19.26, 14.54, 
11.45 (d, J = 2.0 Hz). HRMS (TOF) m/z: 235.1145 (M+H+); calc. for [C14H15FO2+H+]: 
235.1129. 
 
Ethyl 2-ethyl-3-(4-fluorophenyl)cycloprop-2-ene-1-carboxylate (2e) 
 
1H NMR (400 MHz, CDCl3) δ 7.51 – 7.38 (m, 2H), 7.13 – 7.04 (m, 
2H), 4.23 – 4.07 (m, 2H), 2.68 (q, J = 7.5 Hz, 2H), 2.43 (s, 1H), 1.32 
(t, J = 7.5 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 175.89, 162.92 (d, J = 250.2 Hz), 131.25 (d, J = 8.5 Hz), 
123.53 (d, J = 3.4 Hz), 115.97 (d, J = 22.1 Hz), 111.17, 103.71, 60.32, 22.37, 19.19, 14.56, 
12.20. HRMS (TOF) m/z: 235.1134 (M+H+); calc. for [C14H15FO2+H+]: 235.1129. 
 
Ethyl 2-ethyl-3-(3-methoxyphenyl)cycloprop-2-ene-1-carboxylate (2f) 
 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.27 (m, 1H), 7.08 (dt, J = 
7.6, 1.2 Hz, 1H), 6.99 (dd, J = 2.7, 1.5 Hz, 1H), 6.87 (ddd, J = 8.3, 
2.6, 1.0 Hz, 1H), 4.22 – 4.08 (m, 2H), 3.83 (s, 3H), 2.69 (q, J = 7.5 
Hz, 2H), 2.44 (s, 1H), 1.33 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 175.96, 159.84, 129.81, 128.46, 122.06, 114.69, 
114.52, 112.03, 104.69, 60.26, 55.47, 22.48, 19.30, 14.57, 12.18. HRMS (TOF) m/z: 
247.1331 (M+H+); calc. for [C15H18O3+H+]: 247.1329. 
 
Ethyl 2-ethyl-3-(4-trifluoromethylphenyl)cycloprop-2-ene-1-carboxylate (2g) 
 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.1 Hz, 2H), 7.57 (d, J 
= 8.1 Hz, 2H), 4.16 (qd, J = 7.1, 5.3 Hz, 2H), 2.73 (q, J = 7.5 Hz, 
2H), 2.49 (s, 1H), 1.34 (t, J = 7.5 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.40, 130.72 (q, J = 2.2 Hz), 
130.07 (q, J = 32.8 Hz), 129.57, 125.76 (q, J = 3.9 Hz), 124.11 (q, 











285.1118 (M+H+); calc. for [C15H15F3O2+H+]: 285.1097. 
 
Ethyl 2-ethyl-3-(4-(difluoromethoxy)phenyl)cycloprop-2-ene-1-carboxylate (2h) 
 
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 2H), 7.14 (d, 
J = 8.8 Hz, 2H), 6.52 (t, J = 73.6 Hz, 1H), 4.21 – 4.09 (m, 2H), 
2.69 (q, J = 7.5 Hz, 2H), 2.44 (s, 1H), 1.32 (t, J = 7.5 Hz, 3H), 
1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.80, 
151.30 (t, J = 2.7 Hz), 130.95, 124.64, 119.87, 115.85 (t, J = 
261.4 Hz), 111.95, 103.70, 60.35, 22.36, 19.25, 14.56, 12.20. HRMS (TOF) m/z: 283.1139 
(M+H+); calc. for [C15H16F2O3+H+]: 283.1140. 
 
Ethyl 2-ethyl-3-(p-tolyl)cycloprop-2-ene-1-carboxylate (2i) 
 
1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.1 Hz, 2H), 7.19 (d, J = 
7.8 Hz, 2H), 4.21 – 4.06 (m, 2H), 2.67 (q, J = 7.5 Hz, 2H), 2.42 (s, 
1H), 2.37 (s, 3H), 1.32 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 176.20, 138.79, 129.49, 129.42, 
124.38, 110.28, 104.50, 60.19, 22.30, 21.60, 19.25, 14.57, 12.24. HRMS (TOF) m/z: 
231.1378 (M+H+); calc. for [C15H18O2+H+]: 231.1380. 
 
Ethyl 2-ethyl-3-(4-methoxyphenyl)cycloprop-2-ene-1-carboxylate (2j) 
 
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.8 Hz, 2H), 6.92 (d, J 
= 8.9 Hz, 2H), 4.20 – 4.09 (m, 2H), 3.83 (s, 3H), 2.66 (q, J = 7.4 
Hz, 2H), 2.40 (s, 1H), 1.31 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 176.31, 160.04, 130.93, 
128.47, 119.91, 114.32, 108.80, 104.05, 60.18, 55.50, 22.33, 19.17, 14.58, 12.29. HRMS 
(TOF) m/z: 247.1338 (M+H+); calc. for [C15H18O3+H+]: 247.1329. 
 
Ethyl 2-ethyl-3-(4-chloro-3-methylphenyl)cycloprop-2-ene-1-carboxylate (2k) 
 
1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 
1.4 Hz, 1H), 7.24 (dd, J = 8.2, 1.9 Hz, 1H), 4.21 – 4.08 (m, 2H), 
2.68 (q, J = 7.5 Hz, 2H), 2.42 (s, 1H), 2.38 (s, 3H), 1.32 (t, J = 7.5 
Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
175.84, 136.59, 134.87, 131.70, 129.51, 128.06, 125.74, 112.13, 103.86, 60.32, 22.34, 
20.15, 19.28, 14.55, 12.16. HRMS (TOF) m/z: 265.1002 (M+H+); calc. for 
[C15H17ClO2+H+]: 265.0990. 
 
Ethyl 2-ethyl-3-(4-methoxy-3-methylphenyl)cycloprop-2-ene-1-carboxylate (2l) 
 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 6.83 (d, J = 8.2 
Hz, 1H), 4.14 (dddd, J = 17.9, 10.8, 7.1, 3.7 Hz, 2H), 3.84 (s, 3H), 
2.66 (q, J = 7.5 Hz, 2H), 2.39 (s, 1H), 2.22 (s, 3H), 1.31 (t, J = 7.5 









176.43, 158.32, 131.76, 128.42, 127.19, 119.32, 110.08, 108.38, 104.17, 60.14, 55.55, 
22.32, 19.15, 16.30, 14.59, 12.29. HRMS (TOF) m/z: 261.1463 (M+H+); calc. for 
[C16H20O2+H+]: 261.1485. 
 
Ethyl 2-(2-ethoxyethyl)-3-ethylcycloprop-2-ene-1-carboxylate (2m) 
 
1H NMR (400 MHz, CDCl3) δ 4.11 (q, J = 7.1 Hz, 2H), 3.66 – 
3.55 (m, 2H), 3.49 (qd, J = 7.0, 0.7 Hz, 2H), 2.69 (tq, J = 6.9, 1.5 
Hz, 2H), 2.43 (qt, J = 7.5, 1.5 Hz, 2H), 2.07 (s, 1H), 1.24 (t, J = 
7.1 Hz, 3H), 1.19 (t, J = 7.0 Hz, 3H), 1.14 (t, J = 7.5 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 177.01, 108.55, 102.81, 67.90, 66.38, 59.98, 25.58, 22.19, 
18.35, 15.32, 14.56, 11.64. HRMS (TOF) m/z: 213.1481 (M+H+); calc. for [C12H20O3+H+]: 
213.1485. 
 
Ethyl 2-(methoxymethyl)-3-pentylcycloprop-2-ene-1-carboxylate (2n) 
 
1H NMR (400 MHz, CDCl3) δ 4.37 (t, J = 1.5 Hz, 2H), 4.12 
(q, J = 7.1 Hz, 2H), 3.39 (s, 3H), 2.47 (tt, J = 7.5, 1.5 Hz, 2H), 
2.20 (s, 1H), 1.63 – 1.52 (m, 2H), 1.32 (tt, J = 6.7, 3.5 Hz, 
4H), 1.24 (t, J = 7.1 Hz, 3H), 0.93 – 0.85 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 176.17, 
110.25, 102.48, 65.78, 60.19, 58.58, 31.54, 26.65, 24.68, 22.71, 22.48, 14.53, 14.13. 
HRMS (TOF) m/z: 227.1626 (M+H+); calc. for [C13H22O3+H+]: 227.1642. 
 
Ethyl 3-methoxydec-4-ynoate (2n-1) 
 
The title compound 2n-1 was synthesized following the 
procedure described in ref (6). 1H NMR (400 MHz, CDCl3) 
δ 4.39 (ddt, J = 8.2, 5.4, 2.0 Hz, 1H), 4.16 (qd, J = 7.2, 1.0 
Hz, 2H), 3.39 (s, 3H), 2.73 (dd, J = 15.5, 8.4 Hz, 1H), 2.63 
(dd, J = 15.5, 5.4 Hz, 1H), 2.20 (td, J = 7.1, 2.0 Hz, 2H), 1.50 (p, J = 7.4 Hz, 2H), 1.40 – 
1.28 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 170.35, 87.30, 77.48, 67.75, 60.79, 56.57, 41.70, 31.11, 28.39, 22.30, 18.75, 14.32, 14.12. 




Compound 2n-2 was isolated from a large-scale enzymatic 
reaction using alkyne 1n and EDA as substrates and C10-PVV 
as the enzyme variant (See Section VII for details for analysis of related enzymatic 
reactions). 1H NMR (400 MHz, CDCl3) δ 5.08 (s, 1H), 4.17 (s, 2H), 4.03 (q, J = 7.1 Hz, 
2H), 3.32 (s, 3H), 2.50 (t, J = 7.5 Hz, 2H), 1.62 – 1.54 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H), 
1.35 – 1.22 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 159.24, 
143.80, 116.69, 81.16, 66.73, 66.20, 57.73, 31.41, 28.57, 25.76, 22.54, 14.76, 14.16. 
HRMS (TOF) m/z: 227.1641 (M+H+); calc. for [C13H22O3+H+]: 227.1642. The isolated 
























V. Scope of Enzymatic Synthesis of Internal Aromatic Cyclopropenes 
 
All enzymatic reactions for internal cyclopropene formation in analytical scale were 
conducted following the general procedure described below and analyzed with gas 
chromatography (GC). All TTNs for the different products were determined using the GC 
standard curves of the corresponding racemic standard products made with Rh2(OAc)4. 
 
General procedure for analytical-scale reactions:  
To a 2 mL vial were added degassed suspension of E. coli expressing the P411-C10 variant 
in M9-N buffer (OD600 = 15 or 20, 340 μL), internal aromatic alkynes (10 μL of 400 mM 
stock solution in EtOH, 10 mM), EDA (10 μL of 400 stock solution in EtOH, 10 mM, 1.0 
equiv.), D-glucose (40 μL of 250 mM stock solution in M9-N buffer, 25 mM) under 
anaerobic conditions. The vial was capped and shaken at 600 rpm at room temperature for 
16 h. Reactions for every substrate were set up in quadruplicate. After the reactions were 
completed, internal standard 1,3,5-trimethoxybenzene (for 2a to 2e, 2g to 2i and 2l) or 
1,2,3-trimethoxybenzne (for 2f, 2j and 2k) (20 μL of 20 mM stock solution in toluene) was 
added to the reaction vials followed by mixed solvent (hexane/ethyl acetate = 1:1, 1 mL). 
The mixture was transferred to a 1.7 mL microcentrifuge tube, and then vortexed (15 
seconds × 3) and centrifuged (14,000 rpm, 5 min) to completely separate the organic and 
aqueous layers. 0.8 mL of organic layer was taken for GC analysis. TTN was calculated 
based on measured protein concentration. Enantiomeric excess was measured by chiral 
HPLC. The absolute configuration of the cyclopropene compounds was not determined. 
 
GC standard curve: 
All data points represent the average of duplicate runs. The calibration curves depict 
product concentration in mM (y-axis) against the ratio of product area to internal standard 
area on the GC (x-axis). 
 
Ethyl 2-ethyl-3-phenylcycloprop-2-ene-1-carboxylate (2a) 
GC calibration curve: 
  
 


























Analysis Data (WIRF, OD600=15): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2a-(1) 6839.6 806.9 8.476 6.03 2.26 2671  
2a-(2) 6587.7 776.4 8.485 6.03 2.26 2673  
2a-(3) 6650.3 779.8 8.528 6.06 2.26 2686  
2a-(4) 6678.4 789.6 8.458 6.01 2.26 2665 2674 
 
Chiral HPLC trace: 




Area% report for racemic and enzymatically produced 2a:  











9.45 3903.5 51.03 - - - 
13.04 3745.9 48.97 12.97 13104.9 100.00 


















Ethyl 2-ethyl-3-(4-chorophenyl)cycloprop-2-ene-1-carboxylate (2b) 
GC calibration curve: 
  
 
Analysis Data (WIRF_GAK, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2b-(1) 6612.8 780.1 8.477 4.62 2.18 2124  
2b-(2) 6951.3 789.3 8.807 4.81 2.18 2210  
2b-(3) 6318.4 783.2 8.067 4.39 2.18 2018  
2b-(4) 6829.4 789.4 8.651 4.72 2.18 2169 2130 
 
Chiral HPLC trace: 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 



























Area% report for racemic and enzymatically produced 2b:  











6.20 10374.7 49.98 - - - 
7.84 10382.2 50.02 7.95 14886.3 100.00 
Total 20756.9 100.00 Total 14886.3 100.00 
 
Ethyl 2-methyl-3-phenylcycloprop-2-ene-1-carboxylate (2c) 
GC calibration curve: 
  
Analysis Data (WIRF, OD600=15): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2c-(1) 6449.8 776.8 8.303 5.47 2.26 2426  
2c-(2) 6363.9 784.1 8.116 5.35 2.26 2370  
2c-(3) 5895.1 779.2 7.566 4.98 2.26 2207  
2c-(4) 6059.4 756.8 8.007 5.27 2.26 2338 2335 
 
Chiral HPLC trace: 
Chiralpak IC, 2.8% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 





























Area% report for racemic and enzymatically produced 2c:  











8.81 7897.2 49.93 - - - 
11.50 7918.6 50.07 11.88 28691.3 100.00 
Total 15815.8 100.00 Total 28691.3 100.00 
 
Ethyl 2-ethyl-3-(2-fluorophenyl)cycloprop-2-ene-1-carboxylate (2d) 
GC calibration curve: 
  
 


























Analysis Data (WIRF, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2d-(1) 6031.1 769.7 7.836 3.83 3.01 1273  
2d-(2) 5341.5 767.4 6.961 3.40 3.01 1129  
2d-(3) 5778.2 778.0 7.427 3.63 3.01 1206  
2d-(4) 5862.0 793.9 7.384 3.61 3.01 1198 1201 
 
Chiral HPLC trace: 




Area% report for racemic and enzymatically produced 2d:  











7.04 9178.0 50.14 - - - 
8.80 9127.6 49.86 8.74 13107.2 100.00 














Ethyl 2-ethyl-3-(4-fluorophenyl)cycloprop-2-ene-1-carboxylate (2e) 
GC calibration curve: 
  
 
Analysis Data (WIRF_G, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2e-(1) 6531.9 788.0 8.289 4.27 2.69 1589  
2e-(2) 6825.3 801.1 8.520 4.39 2.69 1634  
2e-(3) 6455.4 793.5 8.135 4.19 2.69 1560  
2e-(4) 6645.0 772.6 8.601 4.43 2.69 1649 1608 
 
Chiral HPLC trace: 




Area% report for racemic and enzymatically produced 2e:  




































6.00 11344.7 49.84 - - - 
6.88 11418.2 50.16 6.87 16055.4 100.00 
Total 22762.9 100.00 Total 16055.4 100.00 
 
Ethyl 2-ethyl-3-(3-methoxyphenyl)cycloprop-2-ene-1-carboxylate (2f) 
GC calibration curve: 
  
 
Analysis Data (WIRF_G, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2f-(1) 2136.3 808.3 2.643 1.27 2.69 472  
2f-(2) 2365.8 793.6 2.981 1.43 2.69 533  
2f-(3) 2582.1 791.1 3.264 1.57 2.69 584  
2f-(4) 2161.4 798.1 2.708 1.30 2.69 484 519 
 
Chiral HPLC trace: 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
 



























Area% report for racemic and enzymatically produced 2f:  











14.28 9133.9 50.03 - - - 
16.34 9122 49.97 16.41 6722.22 100.00 
Total 18255.9 100.00 Total 6722.22 100.00 
 
Ethyl 2-ethyl-3-(4-trifluoromethylphenyl)cycloprop-2-ene-1-carboxylate (2g) 
GC calibration curve: 
  
 
Analysis Data (WIRF_GAK, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2g-(1) 4817.3 781.3 6.166 3.13 2.18 1440  
2g-(2) 5442.6 810.4 6.716 3.41 2.18 1568  
2g-(3) 5254.5 795.8 6.603 3.36 2.18 1542  
2g-(4) 5083.1 790.7 6.429 3.27 2.18 1501 1513 
 
Chiral HPLC trace: 






























Area% report for racemic and enzymatically produced 2g:  











5.71 4652.4 51.70 - - - 
5.93 4346.5 48.30 5.91 9992.6 100.00 
Total 8998.9 100.00 Total 9992.6 100.00 
 
Ethyl 2-ethyl-3-(4-(difluoromethoxy)phenyl)cycloprop-2-ene-1-carboxylate (2h) 
GC calibration curve: 
  


























Analysis Data (WIRF_GAK, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2h-(1) 6396.0 798.8 8.007 3.76 2.18 1728  
2h-(2) 5479.1 797.3 6.872 3.22 2.18 1481  
2h-(3) 5087.7 773.4 6.578 3.08 2.18 1417  
2h-(4) 5472.5 792.5 6.905 3.24 2.18 1488 1529 
 
Chiral HPLC trace: 




Area% report for racemic and enzymatically produced 2h:  











6.91 7905.5 50.00 - - - 
8.15 7905.8 50.00 8.12 9799.3 100.00 











Ethyl 2-ethyl-3-(p-tolyl)cycloprop-2-ene-1-carboxylate (2i) 
GC calibration curve: 
  
 
Analysis Data (WIRF_GAK, OD600=15): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2i-(1) 11891.3 785.0 15.148 9.44 1.63 5782  
2i-(2) 11667.8 788.5 14.797 9.20 1.63 5639  
2i-(3) 12089.5 792.8 15.249 9.50 1.63 5823  
2i-(4) 11862.7 781.8 15.174 9.45 1.63 5792 5759 
 
Chiral HPLC trace: 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 




























Area% report for racemic and enzymatically produced 2i:  











8.83 13306.4 49.97 - - - 
17.84 13320.3 50.03 17.49 29535.2 100.00 
Total 26626.7 100.00 Total 29535.2 100.00 
 
Ethyl 2-ethyl-3-(4-methoxyphenyl)cycloprop-2-ene-1-carboxylate (2j) 
GC calibration curve: 
  
 
Analysis Data (WIRF_GAK, OD600=15): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2j-(1) 10209.8 807.4 12.645 7.30 1.63 4470  
2j-(2) 10484.6 800.1 13.104 7.57 1.63 4639  
2j-(3) 10350.3 811.8 12.750 7.36 1.63 4509  
2j-(4) 9927.8 803.9 12.350 7.12 1.63 4361 4495 
 
 


























Chiral HPLC trace: 




Area% report for racemic and enzymatically produced 2j:  











10.33 7394.3 49.92 - - - 
18.38 7417.0 50.08 18.51 25171.5 100.00 

















Ethyl 2-ethyl-3-(4-chloro-3-methylphenyl)cycloprop-2-ene-1-carboxylate (2k) 
GC calibration curve: 
   
 
Analysis Data (WIRF_GAK, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2k-(1) 4779.0 788.6 6.060 2.46 2.18 1131  
2k-(2) 4771.1 786.6 6.065 2.46 2.18 1132  
2k-(3) 4815.2 763.1 6.310 2.56 2.18 1178  
2k-(4) 4556.0 787.0 5.789 2.35 2.18 1080 1130 
 
Chiral HPLC trace: 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 




























Area% report for racemic and enzymatically produced 2k:  











6.31 21041.9 49.45 - - - 
6.96 21508.1 50.55 6.90 10024.1 100.00 
Total 42550.0 100.00 Total 10024.1 100.00 
 
Ethyl 2-ethyl-3-(4-methoxy-3-methylphenyl)cycloprop-2-ene-1-carboxylate (2l) 
GC calibration curve: 
   
 
Analysis Data (WIRF_GAK, OD600=20): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2l-(1) 7021.1 797.6 8.803 3.73 2.18 1714  
2l-(2) 7502.1 809.4 9.269 3.94 2.18 1809  
2l-(3) 6806.2 807.3 8.431 3.56 2.18 1638  
2l-(4) 7147.9 807.5 8.852 3.75 2.18 1724 1721 
 
 

























Chiral HPLC trace: 




Area% report for racemic and enzymatically produced 2l:  











9.30 8567.5 49.90 - - - 
12.53 8601.3 50.10 12.49 13311.0 100.00 







VI. Enzymatic Preparation of Internal Cyclopropenes and Derivatization 
 
Enzymatic reactions for internal cyclopropenation in preparative scale were conducted 
following the procedure described below, and the corresponding cyclopropene products 
were isolated. 
 
General procedure for preparative-scale reactions:  
To a 500 mL flask were added a suspension of E. coli expressing P411-C10 variant 
(OD600 = 15), alkyne (1.0 mmol), EDA (0.8 mmol, 0.8 equiv.), D-glucose (20 mM), M9-
N buffer/EtOH (20:1 v/v) under anaerobic conditions. The flask was capped and shaken 
(300 rpm) inside the anaerobic chamber at room temperature for 2 h. The second portion 
of EDA (0.8 mmol, 0.8 equiv.) was added to the reaction before the reaction was shaken 
for another 2 h and a third portion of EDA (0.8 mmol, 0.8 equiv.) was then added. The 
reaction was shaken for another 20 h. 
After the reaction was completed, the reaction mixture were transferred to 500 mL 
centrifuge bottle. The reaction flask was washed with water (3 mL × 3) followed by mixed 
organic solvent (hexane/ethyl acetate = 1:1, 5 mL × 3). The washing solution was combined 
with the reaction mixture in the centrifuge bottle. An additional 100 mL of hexane/ethyl 
acetate solvent was added to the centrifuge bottle. After the bottle was capped, it was 
shaken vigorously and centrifuged (6,000 × g, 6 min). The organic layer was separated and 
the aqueous layer was subjected to three more rounds of extraction. The organic layers 
were combined, dried over Na2SO4 and concentrated under reduced pressure. Purification 
by silica column chromatography with hexane/ethyl acetate as eluents followed by C18 
column reverse-phase chromatography using acetonitrile/water as eluents afforded the 
desired cyclopropenes. TTNs were calculated based on measured protein concentration and 
isolated product yield. 
 
Ethyl 2-ethyl-3-(2-fluorophenyl)cycloprop-2-ene-1-carboxylate (2d) 
 
E. coli suspension expressing WIRF in M9-N D-glucose 
OD600 volume/mL [PC]/μM n_pro/μmol Mass/g [Glu]/mM 
15 200 3.11 0.621 0.75 ~20 
alkyne (2d) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
0.50 2.00 1.00 0.8 1.00 × 3 2.4 
purification eluent Product 
Silica column: EtOAc in 
hexanes (0% to 10% 
gradient) 
C18 column: MeCN in 
H2O (0% to 100% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 





Ethyl 2-ethyl-3-(4-trifluoromethylphenyl)cycloprop-2-ene-1-carboxylate (2g) 
 
E. coli suspension expressing WIRF_GAK in M9-N D-glucose 
OD600 volume/mL [PC]/μM n_pro/μmol Mass/g [Glu]/mM 
15 200 1.75 0.351 0.75 ~20 
alkyne (2d) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
0.50 2.00 1.00 0.8 1.00 × 3 2.4 
purification eluent Product 
Silica column: EtOAc in 
hexanes (0% to 10% 
gradient) 
C18 column: MeCN in 
H2O (0% to 100% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
245.8 0.865 87% 2465 
 
Note: [PC] = protein concentration in original cell suspension, n_pro = amount of protein 
in the reaction, [Glu] = D-glucose concentration in reaction mixture, n_1 = amount of 
alkyne in the reaction, n_2 = amount of EDA in the reaction, m[Pdt] = mass of product 
isolated, n[Pdt] = amount of product. The same for the next table. 
 
All-cis ethyl 2-ethyl-3-(2-fluorophenyl)cyclopropane-1-carboxylate (3a) 
 
Product 2d (46.9 mg, 0.2 mmol) from enzymatic reaction was dissolved 
in toluene (2 mL) in a vial and then Pd/C (10.6 mg, 10% palladium on 
carbon, 5 mol% Pd) was added to the solution. The vial was then 
capped, and the solution was degassed with H2 using a H2 balloon. The 
reaction was then stirred under H2 atmosphere at room temperature for 12 h. After the 
reaction is completed, the organic solvent was removed under reduced pressure. 
Purification by silica column chromatography with hexane/ethyl acetate as eluents afforded 
the desired all-cis cyclopropane product 3a (47.1 mg, >99% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.25 – 7.15 (m, 2H), 7.05 (td, J = 7.5, 1.3 Hz, 1H), 6.99 (ddd, J = 9.9, 8.6, 1.3 
Hz, 1H), 4.06 (qd, J = 7.2, 2.2 Hz, 2H), 2.48 (td, J = 8.8, 1.1 Hz, 1H), 2.13 (t, J = 8.6 Hz, 
1H), 1.91 – 1.76 (m, 1H), 1.72 – 1.57 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.01, 162.63 (d, J = 246.9 Hz), 132.10 (d, J = 4.1 
Hz), 128.40 (d, J = 8.4 Hz), 123.48 (d, J = 3.6 Hz), 122.86 (d, J = 15.1 Hz), 115.12 (d, J = 
22.1 Hz), 60.09, 27.24, 23.39 (d, J = 1.8 Hz), 21.70 (d, J = 1.4 Hz), 17.47, 14.33, 14.04. 








All-cis (2-ethyl-3-(2-fluorophenyl)cyclopropyl)methanol (3b) 
 
Cyclopropane 3a (47.1 mg, 0.2 mmol) was dissolved in anhydrous THF 
(2 mL) in a 50 mL flask, which was then placed in an ice-water bath. 
LiAlH4 (15.2 mg, 0.4 mmol, 2.0 equiv.) was slowly added to the 
solution. The reaction was allowed to slowly warm to room temperature 
over 1 h and then stirred for another 1h. NaOH (2 mL, 1M aq.) was added to quench the 
reaction. The crude product was extracted with ether (10 mL × 4). The combined organic 
layer was dried over Na2SO4 and concentrated under reduced pressure. Purification by 
silica column chromatography with hexane/ethyl acetate as eluents afforded the desired 
all-cis cyclopropane product 3b (36.4 mg, 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.34 
(tdd, J = 7.6, 1.9, 1.1 Hz, 1H), 7.23 – 7.16 (m, 1H), 7.09 – 6.97 (m, 2H), 3.68 (d, J = 7.4 
Hz, 2H), 2.13 (td, J = 8.8, 1.1 Hz, 1H), 1.65 – 1.51 (m, 3H), 1.34 – 1.25 (m, 1H), 1.17 – 
1.02 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 163.05 (d, J = 245.5 Hz), 132.44 (d, J = 4.2 
Hz), 128.13 (d, J = 8.4 Hz), 124.47 (d, J = 15.5 Hz), 123.93 (d, J = 3.5 Hz), 115.43 (d, J = 
22.7 Hz), 60.18 (d, J = 1.5 Hz), 21.93, 21.66, 18.60 (d, J = 2.8 Hz), 18.51, 14.70. HRMS 






VII. Enzymatic Carbene Transfer to Internal Aliphatic Alkynes 
 
All enzymatic reactions for internal cyclopropene formation and related in analytical scale 
were conducted following the general procedure described below and analyzed with gas 
chromatography (GC). All TTNs for the different products were determined using the GC 
standard curve of the corresponding racemic standard product. 
 
General procedure for analytical-scale reactions:  
To a 2 mL vial were added degassed suspension of E. coli expressing the P411 variant in 
M9-N buffer (OD600 = 15 or 20, 340 μL), internal aliphatic alkynes (10 μL of 400 mM 
stock solution in EtOH, 10 mM), EDA (10 μL of 400 stock solution in EtOH, 10 mM, 1.0 
equiv.), D-glucose (40 μL of 250 mM stock solution in M9-N buffer, 25 mM) under 
anaerobic conditions. The vial was capped and shaken at 600 rpm at room temperature for 
16 h. Reactions for every substrate were set up in quadruplicate. After the reactions were 
completed, internal standard ethyl 2-phenylacetate (20 μL of 20 mM stock solution in 
toluene) was added to the reaction vials followed by mixed solvent (hexane/ethyl acetate 
= 1:1, 1 mL). The mixture was transferred to a 1.7 mL microcentrifuge tube, and then 
vortexed (15 seconds × 3) and centrifuged (14,000 rpm, 5 min) to completely separate the 
organic and aqueous layers. 0.8 mL of organic layer was taken for GC analysis. TTN was 
calculated based on measured protein concentration. Enantiomeric excess was measured 
by chiral GC. 
 
GC standard curve: 
All data points represent the average of duplicate runs. The calibration curves depict 
product concentration in mM (y-axis) against the ratio of product area to internal standard 
area on the GC (x-axis). 
 
Ethyl 2-(2-ethoxyethyl)-3-ethylcycloprop-2-ene-1-carboxylate (2m) 






























Analysis Data (C10, OD600=15): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2m-(1) 125.9 1066.5 0.118 0.11 2.34 46  
2m-(2) 123.4 1041.9 0.118 0.11 2.34 46  
2m-(3) 125.5 1032.3 0.122 0.11 2.34 47  
2m-(4) 118.2 1047.3 0.113 0.10 2.34 44 46 
 
Analysis Data (C10-T327V Q437L S332C, OD600=15): 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
2m-(1) 211.5 1039.4 0.203 0.17 2.57 64  
2m-(2) 217.2 1056.9 0.206 0.17 2.57 65  
2m-(3) 212.3 1055.3 0.201 0.16 2.57 64  
2m-(4) 208.6 1024.0 0.204 0.17 2.57 64 64 
 
Chiral GC trace: 
CycloSil-B, 88 °C isothermal for 92 min -> 2°C/min gradient -> 110°C isothermal for 3 















Area% report for racemic and enzymatically produced 2m:  











85.56 400.29 49.63 85.64 2.47 0.49 
86.67 406.21 50.37 86.69 500.01 99.51 
Total 806.50 100.00 Total 500.48 100.00 






85.60 3.48 0.46 
86.61 759.84 99.54 
Total 763.32 100.00 
 
Chemoselectivity in carbene transfer to internal alkyne 1n with different P411 variants: 
 
 
Ethyl 2-(methoxymethyl)-3-pentylcycloprop-2-ene-1-carboxylate (2n) 





























HP5 column, 80 °C isothermal for 2 min -> 6°C/min gradient -> 180°C -> 60 °C/min 







With C10-Q437I V328I 
(C10_II) 
With C10-A87P A264S 
E267D T327P S332A 
Q437L (L8) 
With P411-CHF 
With C10-G74T S118M 










14.24 min 14.33 min 14.42 min 
Compound 
# 






TTN for all products based on carbene transfer (OD600=20 for L8, OD600=15 for the rest): 
Pdt- 
Entries 




n-(1) 309.4 1026 0.302 0.24 2.72 90  
2n-1:2n:2n-2 
30:60:10 
n-(2) 272.1 989.2 0.275 0.22 2.72 82  
n-(3) 283.4 1021.1 0.278 0.23 2.72 83  









n-(1) 272.7 1064.9 0.256 0.21 2.90 72  
2n-1:2n:2n-2 
5:80:15 
n-(2) 259.5 988.2 0.263 0.21 2.90 74  
n-(3) 257.1 987.8 0.260 0.21 2.90 73  








n-(1) 394.9 1028.2 0.384 0.31 2.34 133  
2n-1:2n:2n-2 
22:70:8 
n-(2) 395.2 1015.3 0.389 0.32 2.34 135  
n-(3) 402.1 1010.6 0.398 0.32 2.34 138  



















n-(1) 759 1002.5 0.757 0.61 2.20 278  
2n-1:2n:2n-2 
67:30:3 
n-(2) 747.3 1006.1 0.743 0.60 2.20 272  
n-(3) 720.9 1008.8 0.715 0.58 2.20 262  













n-(2) 1176.6 992.0 1.186 0.95 2.44 389  
n-(3) 1170.9 992.9 1.179 0.95 2.44 387  













n-(2) 229.3 1004.4 0.228 0.19 3.03 61  
n-(3) 224.9 991.0 0.227 0.18 3.03 61  
n-(4) 233.1 1016.0 0.229 0.19 3.03 62 61 
 
Chiral GC trace: 
CycloSil-B, 100 °C isothermal for 20 min -> 0.2°C/min gradient -> 120°C isothermal for 









Area% report for racemic 2n, 2n-1 and non-chiral 2n-2:  











118.18 58.08 50.06 128.19 2479.29 49.90 
118.88 57.94 49.94 130.63 2489.35 50.10 







124.92 978.08 100.00 
 
 
Area% report for 2n and 2n-1 in the enzymatic reactions with C10:  











117.89 1.77 0.10 129.85 21.91 2.47 
118.47 1836.33 99.90 131.49 864.68 97.53 










Area% report for 2n and 2n-1 in the enzymatic reactions with C10_II:  











117.85 0.84 0.08 129.98 2.15 3.41 
118.44 1116.91 99.92 132.12 59.87 96.59 
Total 1117.75 100.00 Total 63.02 100.00 
 
  
Area% report for 2n and 2n-1 in the enzymatic reactions with L8:  











117.84 4.49 0.32 129.70 26.91 6.35 
118.37 1398.48 99.68 131.68 396.70 93.65 
Total 1402.97 100.00 Total 423.61 100.00 
 
 
Area% report for 2n and 2n-1 in the enzymatic reactions with CHF:  











118.00 1.24 0.13 129.56 24.90 1.22 
118.61 968.48 99.87 130.83 2021.91 98.78 
Total 969.72 100.00 Total 2046.81 100.00 
 
With C10-A87P A264S 








Area% report for 2n and 2n-1 in the enzymatic reactions with C11:  











- - - 129.51 23.65 1.50 
118.65 312.97 100.00 130.88 1549.75 98.50 
Total 969.72 100.00 Total 1573.40 100.00 
 
 
Area% report for 2n and 2n-1 in the enzymatic reactions with C10_PVV:  











118.32 48.08 10.64 129.85 30.70 8.39 
118.78 403.71 89.36 131.95 335.11 91.61 
















With C10-G74T S118M 












VIII. Sequence Information 
 
Mutations present in P411 variants involved in this study: 
P411 
variant 
Mutations relative to wild-type P450BM3 
P411-C10 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263Y H266V T268G A290V A328V 
A330Y L353V I366V C400S I401L T436L L437Q E442K ΔFAD* 
P411CHF 
N70E A74P V78L A82L F87A P142S T175I M177L A184V S226R 
H236Q E252G I263Y H266V T268G A290V A328V A330Y L353V 
I366V C400S T436L E442K ΔFAD* 
C10-W 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263W H266V T268G A290V A328V 
A330Y L353V I366V C400S I401L T436L L437Q E442K ΔFAD* 
C10-WI 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263W H266V T268G A290V A328V 
A330Y L353V I366V C400S I401L T436L L437I E442K ΔFAD* 
C10-WIF 
N70E S72F A74G V78L A82L F87A M118S P142S F162L T175I 
M177L A184V S226R H236Q E252G I263W H266V T268G A290V 
A328V A330Y L353V I366V C400S I401L T436L L437I E442K 
ΔFAD* 
C10-WIRF 
N70E S72F A74G V78L A82L F87A M118S P142S F162L T175I 
M177L A184V S226R H236Q E252G I263W H266V T268G A290V 




N70E S72F A74G V78L A82L F87A M118S P142S F162L T175I 
M177L A184V S226R H236Q E252G I263W H266V T268G A290V 




N70E S72F V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263W H266V T268G A290V A328V 




N70K S72F V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263W H266V T268G A290V A328V 
A330Y S332G L353V I366V C400S I401L T436R L437I E442K 
ΔFAD* 
C10-VLC 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263Y H266V T268G A290V T327V 
A328V A330Y S332C L353V I366V C400S I401L T436L E442K 
ΔFAD* 
P411-C11 
N70E A74T V78L A82L F87A P142S T175I M177L A184V S226R 
H236Q E252G I263Y H266V T268G A290V A328V A330Y L353V 
I366V C400S T436L E442K ΔFAD* 
P411-L8 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L 





A290V T327P A328V A330Y S332A L353V I366V C400S I401L 
T436L E442K ΔFAD* 
C10-II 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263Y H266V T268G A290V A328I 
A330Y L353V I366V C400S I401L T436L L437I E442K ΔFAD* 
C10-PVV 
N70E A74G V78L A82L F87V M118S P142S F162L T175I M177L 
A184V S226R H236Q E252G I263Y H266V T268G A290V T327V 
A328V A330Y L353V I366V C400S I401L T436L L437P E442K 
ΔFAD* 
*ΔFAD: FAD domain truncation. 
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